Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial Cancer
A standard treatment for endometrial cancer is chemotherapy and pembrolizumab together followed by pembrolizumab maintenance for two years. This treatment regimen has shown benefit in terms of delaying cancer progression in prior clinical trials, but the benefit of the pembrolizumab maintenance treatment and whether all participants need it is unclear. This research is being done on the maintenance portion of treatment to compare the efficacy between the combination of letrozole + abemaciclib and pembrolizumab alone following chemotherapy and pembrolizumab.
The names of the study drugs involved in this study are:
Abemaciclib (a type of cyclin-dependent kinase (CDK) inhibitor)
Letrozole (a type of aromatase inhibitor)
Pembrolizumab (a type of monoclonal antibody)
A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
100 Clinical Results associated with ER Positive Endometrial Carcinoma
100 Translational Medicine associated with ER Positive Endometrial Carcinoma
0 Patents (Medical) associated with ER Positive Endometrial Carcinoma